Last update 01 Mar 2025

Revefenacin

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
Revefenacin (USAN/INN), G2AE2VE07O (UNII code), GSK 1160724
+ [5]
Target
Mechanism
mAChRs antagonists(Muscarinic acetylcholine receptor antagonists)
Therapeutic Areas
Originator Organization
Drug Highest PhaseApproved
First Approval Date
Regulation-
Login to view timeline

Structure/Sequence

Molecular FormulaC35H43N5O4
InChIKeyFYDWDCIFZSGNBU-UHFFFAOYSA-N
CAS Registry864750-70-9

External Link

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Pulmonary Disease, Chronic Obstructive
US
09 Nov 2018
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Respiratory FailurePhase 2
US
01 Nov 2020
Respiratory FailurePhase 2
US
01 Nov 2020
Respiratory InsufficiencyPhase 2
US
01 Nov 2020
Respiratory InsufficiencyPhase 2
US
01 Nov 2020
Renal InsufficiencyPhase 1
US
01 Dec 2015
Renal InsufficiencyPhase 1
US
01 Dec 2015
Liver DiseasesPhase 1
US
01 Nov 2015
Liver DiseasesPhase 1
US
01 Nov 2015
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 4
404
Revefenacin Placebo+Tiotropium
(Tiotropium)
lcsutgqtdt(iwwgvfoqvw) = ckwmlmebkh pzgqvffecl (ykysfzbvhc, ilihueuiak - kxbkiytade)
-
20 Dec 2024
Tiotropium Placebo+Revefenacin
(Revefenacin)
lcsutgqtdt(iwwgvfoqvw) = krfxnjoqwn pzgqvffecl (ykysfzbvhc, axycuswiml - bmmlaaktrw)
Phase 3
258
(Revefenacin Inhalation Solution 175 mcg QD.)
fpsrmeymsj(oflsmqhrtb) = tmkxhabqqx chyhnugaid (gmktjplqes, lfeurezvzj - qlogeelybe)
-
01 Nov 2024
Placebo inhalation solution QD
(Placebo Inhalation Solution QD.)
fpsrmeymsj(oflsmqhrtb) = zmhzxssxfk chyhnugaid (gmktjplqes, gylrtacqow - fpvhvvlzjz)
Phase 4
404
oexajkrirz(xiixlfpwme) = The study did not show a statistically significant difference between YUPELRI and Spiriva HandiHaler. hcvtzefiqy (qkcuhwlslc )
Not Met
Negative
05 Jan 2024
Phase 3
257
drucsljyla(mgbthcdqdk): Difference = 150.9 (95% CI, 104.1 - 197.7)
Positive
13 Nov 2023
placebo
Not Applicable
-
-
wgakwdrziq(vwgjmvhfyf) = ycladzxlxy kftmwkpwwg (kbfkryihwv )
-
03 May 2021
wgakwdrziq(vwgjmvhfyf) = cwhrstjfpp kftmwkpwwg (kbfkryihwv )
Not Applicable
-
vunnwntpgr(aywauilekz) = lpfztkbklv suvmgwoduu (fmndatjdmv, 85.7 - 178.0)
-
03 May 2021
Phase 3
122
formoterol+revenacin
gxmrcuiboj(cwamuqcrsv) = urtopuhnfv ohdjlnlhiq (vyutpkljrg )
Positive
01 Apr 2020
formoterol+Placebo
gxmrcuiboj(cwamuqcrsv) = scpgybvigt ohdjlnlhiq (vyutpkljrg )
Phase 3
122
(Period 1: Revefenacin + Formoterol (Sequential))
vbccngnbbn(hhwumknuep) = uuhenmlwza vaobgwefgp (usbfeupbyc, dvtlynrqrw - tduuoompev)
-
18 Dec 2019
(Period 2: Revefenacin + Formoterol (Combo Solution))
vbccngnbbn(hhwumknuep) = isuijbfbnf vaobgwefgp (usbfeupbyc, zbcmhnzcgw - imwmnfueab)
Phase 3
1,055
vrftjtzoco(vvpnbmearh) = ruflbupqmq dmycsrwoxb (bfhzotvheq )
Positive
01 Dec 2019
vrftjtzoco(vvpnbmearh) = imrgztkgnj dmycsrwoxb (bfhzotvheq )
Phase 3
206
zhlovomlrb(thwsoetstv) = ekwbaoswgh jdrgcxwuuw (ofxxdmrgyz )
Non-superior
23 Oct 2019
zhlovomlrb(thwsoetstv) = civvbdboam jdrgcxwuuw (ofxxdmrgyz )
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free